Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Basic Research

SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial–mesenchymal transition in vitro

Prostate Cancer and Prostatic Diseases volume 16, pages 301–307 (2013)Cite this article

Subjects

Abstract

Background:

The SOX4 transcription factor is involved in the development and cell fate decision. Although upregulation of SOX4 has been described in human prostate cancer (PCa), the prognostic value of SOX4 and its exact role in PCa progression remain unclear.

Methods:

Three tissue microarrays were constructed from 241 Chinese PCa patients who underwent TURP. Immunohistochemistry (IHC) was used to detect the expression of SOX4. Genetic aberrations of epidermal growth factor receptor and HER2 were detected by fluorescence in situ hybridization. The effect of SOX4 on proliferation was evaluated by MTT (methyl thiazolyl tetrazelium), and cell migration and invasion were evaluated by transwell and wound-healing assays. The distribution of cell-cycle phase was analyzed by flow cytometry. Real-time PCR and western blot were used to study transcript and protein levels.

Results:

Using tissue microarray, we found that SOX4 was overexpressed in 33.0% (76/230) Chinese PCa patients by IHC. SOX4 overexpression was significantly associated with high Gleason scores (P=0.009) and the presence of distant metastasis (P=0.023). Additionally, SOX4 overexpression was significantly correlated with high Ki67 labeling index (P=0.005) and tended to associate with amplification of HER2 (P=0.052) in our cohort. Notably, SOX4 was correlated with cancer-specific mortality of PCa patients by Kaplan–Meier analysis (P=0.001). Multivariate Cox regression analysis indicated that SOX4 was an unfavorable independent prognostic factor in Chinese PCas (P=0.017). SOX4 overexpression enhanced proliferation of Vcap cells and siRNA knockdown of SOX4 significantly decreased Vcap cell migration and invasion, suggesting a role of SOX4 in cancer metastasis. Additionally, flow cytometry DNA analysis revealed that siRNA SOX4 leads to significant accumulation of cells in the S phase and marked decrease of cells in the G2/M phase. Further in vitro study revealed that SOX4 silencing could inhibit TGF-β (transforming growth factor-β)-induced epithelial–mesenchymal transition (EMT) in Vcap cells. Overexpression of SOX4 could promote the EMT phenotype in Vcap cells.

Conclusions:

Our results define an important role for SOX4 in the progression of PCa by orchestrating EMT and may serve as a prognostic marker for PCa patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Shen MM, Abate-Shen C . Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24: 1967–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Castelli T, Cimino S, Magno C, Morgia G . Molecular markers for prostatic cancer. Front Biosci (Elite Ed) 2010; 2: 641–656.

    Google Scholar 

  3. Schepers GE, Teasdale RD, Koopman P . Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002; 3: 167–170.

    Article  CAS  PubMed  Google Scholar 

  4. Andersson A, Ritz C, Lindgren D, Eden P, Lassen C, Heldrup J et al. Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status. Leukemia 2007; 21: 1198–1203.

    Article  CAS  PubMed  Google Scholar 

  5. Lin B, Madan A, Yoon JG, Fang X, Yan X, Kim TK et al. Massively parallel signature sequencing and bioinformatics analysis identifies up-regulation of TGFBI and SOX4 in human glioblastoma. PLoS One 2010; 5: e10210.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Liao YL, Sun YM, Chau GY, Chau YP, Lai TC, Wang JL et al. Identification of SOX4 target genes using phylogenetic footprinting-based prediction from expression microarrays suggests that overexpression of SOX4 potentiates metastasis in hepatocellular carcinoma. Oncogene 2008; 27: 5578–5589.

    Article  CAS  PubMed  Google Scholar 

  7. Medina PP, Castillo SD, Blanco S, Sanz-Garcia M, Largo C, Alvarez S et al. The SRY-HMG box gene, SOX4, is a target of gene amplification at chromosome 6p in lung cancer. Hum Mol Genet 2009; 18: 1343–1352.

    Article  CAS  PubMed  Google Scholar 

  8. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006; 66: 3434–3442.

    Article  CAS  PubMed  Google Scholar 

  9. Liu P, Ramachandran S, Ali Seyed M, Scharer CD, Laycock N, Dalton WB et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006; 66: 4011–4019.

    Article  CAS  PubMed  Google Scholar 

  10. Suzuki T, Shen H, Akagi K, Morse HC, Malley JD, Naiman DQ et al. New genes involved in cancer identified by retroviral tagging. Nat Genet 2002; 32: 166–174.

    Article  CAS  PubMed  Google Scholar 

  11. Scharer CD, McCabe CD, Ali-Seyed M, Berger MF, Bulyk ML, Moreno CS . Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res 2009; 69: 709–717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Nauseef JT, Henry MD . Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol 2011; 8: 428–439.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Thompson EW, Newgreen DF, Tarin D . Carcinoma invasion and metastasis: a role for epithelial-mesenchymal transition? Cancer Res 2005; 65: 5991–5995.

    Article  CAS  PubMed  Google Scholar 

  14. Kong D, Banerjee S, Ahmad A, Li Y, Wang Z, Sethi S et al. Epithelial to mesenchymal transition is mechanistically linked with stem cell signatures in prostate cancer cells. PLoS One 2010; 5: e12445.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zhang J, Liang Q, Lei Y, Yao M, Li L, Gao X et al. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. Cancer Res 2012; 72: 4597–4608.

    Article  CAS  PubMed  Google Scholar 

  16. Korshunov A, Sycheva R, Gorelyshev S, Golanov A . Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol 2005; 18: 1258–1263.

    Article  CAS  PubMed  Google Scholar 

  17. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22: 1083–1093.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Jafarnejad SM, Wani AA, Martinka M, Li G . Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion. Am J Pathol 2010; 177: 2741–2752.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Wang L, Zheng Y, Xu H, Yan X, Chang X . Investigate pathogenic mechanism of TXNDC5 in reumatoid arthritis. PLoS One 2013; 8: e53301.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Han B, Nakamura M, Zhou G, Ishii A, Nakamura A, Bai Y et al. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Int J Oncol 2006; 28: 807–814.

    CAS  PubMed  Google Scholar 

  21. Han B, Mehra R, Dhanasekaran SM, Yu J, Menon A, Lonigro J et al. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res 2008; 68: 7629–7637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Han B, Zhou G, Zhang Q, Zhang J, Wang X, Tang W et al. Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol 2004; 4: 335–342.

    CAS  PubMed  Google Scholar 

  23. Bubendorf L, Sauter G, Moch H, Schmid HP, Gasser TC, Jordan P et al. Ki67 labelling index: an independent predictor of progression in prostate cancer treated by radical prostatectomy. J Pathol 1996; 178: 437–441.

    Article  CAS  PubMed  Google Scholar 

  24. Moreno CS . The sex-determining region Y-box 4 and homeobox C6 transcriptional networks in prostate cancer progression: crosstalk with the Wnt, Notch, and PI3K pathways. Am J Pathol 2010; 176: 518–527.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Andersen CL, Christensen LL, Thorsen K, Schepeler T, Sorensen FB, Verspaget HW et al. Dysregulation of the transcription factors SOX4, CBFB and SMARCC1 correlates with outcome of colorectal cancer. Br J Cancer 2009; 100: 511–523.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008; 451: 147–152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Yarden Y . The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37: S3–S8.

    Article  CAS  PubMed  Google Scholar 

  28. Hernes E, Fossa SD, Berner A, Otnes B, Nesland JM. . Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence. Br J Cancer 2004; 90: 449–454.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (Grant No. 81072110 and No. 81171951), Independent Innovation Foundation of Shandong University (Grant No. 2010TB012) and Scientific Research Foundation for Returned Scholars, Ministry of Education of China.

Author information

Author notes

  1. L Wang and J Zhang: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Pathology, Shandong University Medical School, Jinan, China

    L Wang, X Yang, M Qi & B Han

  2. Research Center for Medicinal Biotechnology, Shandong Academy of Medicinal Sciences, Jinan, China

    L Wang

  3. Department of Pharmacology, Shandong Provincial Hospital, Jinan, China

    J Zhang

  4. Department of Health and Disease and Psychology, University of Tornoto, Markham, Ontario, Canada

    Y W Y Chang

  5. Department of Pathology, Shandong University Qilu Hospital, Jinan, China

    Z Zhou, J Zhang & B Han

Authors
  1. L Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y W Y Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Qi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B Han.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, L., Zhang, J., Yang, X. et al. SOX4 is associated with poor prognosis in prostate cancer and promotes epithelial–mesenchymal transition in vitro. Prostate Cancer Prostatic Dis 16, 301–307 (2013). https://doi.org/10.1038/pcan.2013.25

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2013.25

Keywords

This article is cited by

Search

Advanced search

Quick links